Recombinant human growth hormone therapy safely improved growth in a child with brachydactyly type C
Background
Brachydactyly is a rare congenital defect characterized by shortened fingers and/or toes, often inherited in an autosomal dominant pattern. While it can be part of broader syndromes, isolated forms like type C are known to be associated with height deficiency. Current standard-of-care for short stature often targets growth hormone deficiency (GHD). However, the efficacy of recombinant human growth hormone (rhGH) therapy in patients with brachydactyly who exhibit normal endogenous growth hormone secretion has remained an unexplored clinical gap, limiting treatment options for this specific population.
Study Design
This case report documented the effects of recombinant human growth hormone (rhGH) therapy in a single pediatric patient. The subject was a boy diagnosed with brachydactyly type C who presented with short stature, despite having normal growth hormone secretion as confirmed by stimulation tests. The study's primary objective was to evaluate the boy's clinical response to the rhGH treatment and to assess its safety profile. The researchers monitored growth parameters and adverse events throughout the therapy period, providing a detailed account of the intervention's outcomes in this specific, previously undocumented scenario.
Results
The patient demonstrated a positive clinical outcome following recombinant human growth hormone (rhGH) therapy. The boy exhibited a good response to the treatment, indicating an improvement in growth parameters. Importantly, the therapy was also found to be safe, with no adverse events reported during the treatment period. This case represents the first documented instance of rhGH therapy being utilized in a child with brachydactyly type C who had normal endogenous growth hormone secretion, yet still experienced significant height deficiency. The findings suggest a potential therapeutic avenue beyond traditional GHD indications. The literature review accompanying the case report further contextualized these findings within the broader landscape of rhGH use in children with isolated brachydactyly.
The boy showed a good response to rhGH treatment, and the therapy was found to be safe.
Key Findings
- Recombinant human growth hormone (rhGH) therapy improved growth in a child with brachydactyly type C.
- The rhGH treatment was found to be safe, with no reported adverse events.
- Benefit was observed despite the patient having normal endogenous growth hormone secretion.
- This is the first documented case of rhGH therapy in a child with brachydactyly type C and normal GH secretion.
Why It Matters
This case report offers a significant insight for clinicians and patients dealing with brachydactyly-associated short stature, particularly when endogenous growth hormone levels are normal. It suggests that rhGH therapy may be beneficial even in the absence of classical GHD, potentially expanding the eligible patient population for this treatment. For individuals with brachydactyly type C and short stature, this opens a new avenue for improving final adult height, which was previously considered less likely without a diagnosed GH deficiency. While a single case report doesn't establish a universal protocol, it provides compelling preliminary evidence that warrants further investigation, potentially leading to revised clinical guidelines for managing growth in specific congenital limb defects. This could influence future treatment strategies, encouraging trials for off-label rhGH use in similar populations.
recombinant human growth hormone
rhgh
brachydactyly
short stature
growth hormone
pediatric
